90
Participants
Start Date
May 31, 2006
Primary Completion Date
April 30, 2008
Study Completion Date
February 28, 2010
CP-675,206
Given intravenously every 3 months
best supportive care
As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
Research Site, New York
Research Site, Oswego
Research Site, Syracuse
Research Site, Oneida
Research Site, Philadelphia
Research Site, Atlanta
Research Site, Canton
Research Site, Alexandria
Research Site, Fayetteville
Research Site, Bentonville
Research Site, Orange
Research Site, Danbury
Research Site, Lexington
Research Site, Syracuse
Research Site, Calgary
Research Site, Calgary
Research Site, Edmonton
Research Site, Montreal
Research Site, Prague
Research Site, Tábor
Research Site, Ústí nad Labem
Research Site, Seoul
Research Site, Seoul
Research Site, Seoul
Research Site, Southampton
Research Site, London
Lead Sponsor
AstraZeneca
INDUSTRY